Myocardial
ischemia occurs when blood flow to heart muscle or myocardium is obstructed by
a complete or partial blockage of a coronary artery by a buildup of plaques
(atherosclerosis). It is also called cardiac ischemia. The most common symptom
is chest pressure or pain, usually on the left side of the body (angina
pectoris). Some other sign & symptoms are neck or jaw pain, fast heartbeat,
shortness of breath, shoulder or arm pain, sweating, nausea & vomiting and
fatigue.
Some
of the risk factors include high blood pressure, obesity, diabetes, tobacco,
high blood triglyceride level, high blood cholesterol level, waist
circumference, waist circumference and lack of physical activity. Apart from
this, few of the complications include irregular heart rhythm, heart failure
and heart attack.
Based
on type, myocardial ischemia market is segmented into symptomatic and
asymptomatic. Based on condition type, market is segmented into blood clot,
coronary artery disease and coronary artery spasm. Based on treatment &
diagnosis, market is segmented into diagnosis and treatment. Diagnosis segment
is further sub-segmented into stress and imaging tests. Imaging tests include
Electrocardiogram (ECG), coronary angiography, nuclear scan, holter monitoring
and cardiac CT scan. Treatment segment is further sub-segmented into surgery
(angioplasty & stenting, enhanced external counter pulsation and coronary
artery bypass surgery) and medications (antiplatelet agents (vorapaxar, aspirin,
and clopidogre), antithrombotic agents, beta-adrenergic blockers, glycoprotein
IIb/IIIa inhibitors, angiotensin-receptor blockers, thrombolytics (tenecteplase
and alteplase [t-PA]), angiotensin-converting enzyme (ACE) inhibitors, and
analgesics (morphine sulfate)). In addition, based on end-user, market is
segmented into diagnostic centers, hospitals & clinics, ambulatory surgery
centers, and others.
The
myocardial ischemia market is driven by high prevalence of coronary heart
disease, followed by change in lifestyle and rise in incidence of diabetes.
However, side effects related to medications and high cost of therapeutic
surgeries may impact the market. Moreover, increase in acceptance of newer
treatment technologies is a key opportunity for market.
Based
on geography, the North-American region holds major share, followed by European
region in myocardial ischemia market owing to rise in awareness of the
population about cardiovascular diseases, increase in competition from small
market players and growth in technological advancements in the region.
Asian-Pacific region is expected to witness higher growth rate due to increase
in the prevalence of various heart-related diseases and continuously
development in economies over the forecast period. It is anticipated that
future of the market will be bright on account of presence of a well-developed
healthcare sector and huge patient population during the forecast period.
To know more, click on
the link below:-
Related Reports:-
Contact Us:-
Ken
Research
Ankur
Gupta, Head Marketing & Communications
+91-9015378249